Beacon Pointe Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Beacon Pointe Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Sell	18,837 -40	-0.2%	-$47	﹤0.01%	1906
2026 Q1	$25.3K	Buy	+18,877	New	+$31.1K	﹤0.01%	1818
2025 Q3	–	Sell	-18,845	Closed	-$34.1K	–	1393
2025 Q2	$34.1K	Hold	18,845	–	–	﹤0.01%	1241
2025 Q1	$38.3K	Buy	+18,845	New	+$70.4K	﹤0.01%	1203
2024 Q2	–	Sell	-18,858	Closed	-$851K	–	1285
2024 Q1	$851K	Hold	18,858	–	–	0.01%	743
2023 Q4	$890K	Hold	18,858	–	–	0.01%	705
2023 Q3	$763K	Buy	+18,858	New	+$1.91M	0.01%	714
2023 Q1	–	Sell	-18,884	Closed	-$6.49M	–	1151
2022 Q4	$6.49M	Buy	+18,884	New	+$4.57M	0.13%	162

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Beacon Pointe Advisors's BTAI Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its BioXcel Therapeutics (BTAI) stake by 0.21% in Q2 2026, selling an estimated $47 and leaving 18,837 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Beacon Pointe Advisors first reported a position in BTAI in Q4 2022 and has held it in 8 quarters since. The position peaked at $6.49M in Q4 2022. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Beacon Pointe Advisors held 18,837 shares of BioXcel Therapeutics worth $26.6K as of Q2 2026.
Beacon Pointe Advisors sold 40 BioXcel Therapeutics shares in Q2 2026, an estimated $47.
BioXcel Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1906 holding.
Beacon Pointe Advisors first reported a position in BioXcel Therapeutics in Q4 2022 and has held it in 8 quarters since.
Beacon Pointe Advisors's BioXcel Therapeutics position peaked at $6.49M in Q4 2022.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.